Windlas Biotech Limited has received Good Manufacturing Practices (GMP) certification for its new injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand. The certification, based on an inspection conducted in December 2024, confirms compliance with the World Health Organization’s (WHO) TRS guidelines.
The new facility, equipped with advanced technology and automated systems, is designed for the production of sterile injectable formulations. The infrastructure incorporates robust quality control measures and eco-friendly processes to ensure safety and efficiency in production.
This certification extends GMP compliance to all five of Windlas Biotech’s manufacturing plants. The company states that this development will enable an expansion of its product portfolio in the contract development and manufacturing organization (CDMO) space, covering a broader range of therapeutic areas.
Windlas Biotech is a prominent player in the domestic pharmaceutical formulations CDMO sector, with over two decades of experience in manufacturing solid and liquid dosage forms and a growing export portfolio of medical and nutraceutical products.